A Phase 3, randomized study of first-line durvalumab (D) plus /- tremelimumab (T) plus platinum-based chemotherapy (CT) vs CT alone in extensive disease small-cell lung cancer (ED-SCLC): CASPIAN

被引：0
|
作者：
Alt, J. [1 ]
Bischoff, H. G. [2 ]
Laack, H-E [3 ]
Leistner, R. D. [4 ]
Panse, J. [5 ]
Reinmuth, N. [6 ]
Schulz, C. [7 ]
Grohe, C. [8 ]
机构：
[1] Univ Med Mainz, Mainz, Germany
[2] Univ Hosp Heidelberg, Thoraxklin Heidelberg, Heidelberg, Germany
[3] Hamatol Onkol Hamburg, Hamburg, Germany
[4] Sozialstiftung Bamberg, Med Klin Pneumol Allergol & Schlafmed 4, Bamberg, Germany
[5] RWTH Aachen Univ Hosp, Dept Hematol Oncol Hemostaseol & Stem Cell Transp, Aachen, Germany
[6] Asklepios Fachkliniken Gauting, Onkol Klin Pneumol, Gauting, Germany
[7] Klinikum Univ Regensburg, Med Klin & Poliklin 2, Regensburg, Germany
[8] Evangel Lungenklin Berlin Krankenhausbetriebs gGm, Klin Pneumol, Berlin, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2018年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4
引用
收藏
页码：103 / 103
页数：1
相关论文
共 50 条
  • [21] Results of a phase II trial of single-agent amrubicin (AMR) in patients with extensive disease small cell lung cancer (ED-SCLC) refractory to first-line platinum-based chemotherapy: An update
    Ettinger, D. S.
    Jotte, R.
    Lorigan, P.
    Gupta, V.
    Garbo, L.
    Conkling, P.
    Spigel, D.
    McNally, R.
    Renschler, M.
    Oliver, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [22] Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN
    Paz-Ares, L.
    Chen, Y.
    Reinmuth, N.
    Hotta, K.
    Trukhin, D.
    Statsenko, G.
    Hochmair, M. J.
    Ozguroglu, M.
    Ji, J. H.
    Garassino, M. C.
    Voitko, O.
    Poltoratskiy, A.
    Musso, E.
    Havel, L.
    Bondarenko, I
    Losonczy, G.
    Conev, N.
    Mann, H.
    Dalvi, T. B.
    Jiang, H.
    Goldman, J. W.
    ESMO OPEN, 2022, 7 (02)
  • [23] Durvalumab ± tremelimumab plus platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): Updated results from the phase III CASPIAN study.
    Paz-Ares, Luis G.
    Dvorkin, Mikhail
    Chen, Yuanbin
    Reinmuth, Niels
    Hotta, Katsuyuki
    Trukhin, Dmytro
    Statsenko, Galina
    Hochmair, Maximilian
    Ozguroglu, Mustafa
    Ji, Jun Ho
    Voitko, Oleksandr
    Poltoratskiy, Artem
    Verderame, Francesco
    Havel, Libor
    Bondarenko, Igor
    Armstrong, Jon
    Byrne, Natalie
    Jiang, Haiyi
    Goldman, Jonathan Wade
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [24] Randomized phase 2 study of carboplatin plus irinotecan (CI) versus carboplatin plus amrubicin (CA) for extensive disease small-cell lung cancer (ED-SCLC): NJLCG0901.
    Kawashima, Yosuke
    Morikawa, Naoto
    Sugawara, Shunichi
    Maemondo, Makoto
    Harada, Toshiyuki
    Harada, Masao
    Inoue, Akira
    Fujita, Yuka
    Kato, Terufumi
    Yokouchi, Hiroshi
    Watanabe, Hiroshi
    Usui, Kazuhiro
    Suzuki, Toshiro
    Oizumi, Satoshi
    Nagai, Hiroki
    Kanbe, Mariko
    Nukiwa, Toshihiro
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [25] A randomized phase II trial of amrubicin (AMR) vs. topotecan as second-line treatment in extensive-disease small-cell lung cancer (SCLC) sensitive to platinum-based first-line chemotherapy
    Jotte, R. M.
    Conkling, P. R.
    Reynolds, C.
    Allen, A. R.
    Oliver, J. W.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [26] First-line atezolizumab/durvalumab plus platinum–etoposide combined with radiotherapy in extensive-stage small-cell lung cancer
    Lijuan Li
    Dan Yang
    Yanmei Min
    Anyan Liao
    Jing Zhao
    Leilei Jiang
    Xin Dong
    Wei Deng
    Huiming Yu
    Rong Yu
    Jun Zhao
    Anhui Shi
    BMC Cancer, 23
  • [27] Phase II study of topotecan (T) and paclitaxel (P) as first-line treatment in patients (pts) with extensive disease small cell lung cancer (ED-SCLC)
    Hainsworth, J
    Palmer, M
    Granick, J
    Boston, B
    Bonomi, P
    Althouse, D
    Dharan, B
    Poulin, R
    Wissel, P
    LUNG CANCER, 2005, 49 : S320 - S320
  • [28] First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
    Horn, L.
    Mansfield, A. S.
    Szczesna, A.
    Havel, L.
    Krzakowski, M.
    Hochmair, M. J.
    Huemer, F.
    Losonczy, G.
    Johnson, M. L.
    Nishio, M.
    Reck, M.
    Mok, T.
    Lam, S.
    Shames, D. S.
    Liu, J.
    Ding, B.
    Lopez-Chavez, A.
    Kabbinavar, F.
    Lin, W.
    Sandler, A.
    Liu, S. V.
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (23): : 2220 - 2229
  • [29] Durvalumab ± tremelimumab plus platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): 3-year overall survival update from the phase III CASPIAN study
    Paz-Ares, L.
    Chen, Y.
    Reinmuth, N.
    Hotta, K.
    Trukhin, D.
    Statsenko, G.
    Hochmair, M. J.
    Ozguroglu, M.
    Ji, J. H.
    Voitko, O.
    Poltoratskiy, A.
    Verderame, F.
    Havel, L.
    Bondarenko, I.
    Losonczy, G.
    Conev, N. V.
    Broadhurst, H. L.
    Dalvi, T.
    Jiang, H.
    Goldman, J. W.
    ANNALS OF ONCOLOGY, 2021, 32 : S1338 - S1338
  • [30] First-line atezolizumab/durvalumab plus platinum-etoposide combined with radiotherapy in extensive-stage small-cell lung cancer
    Li, Lijuan
    Yang, Dan
    Min, Yanmei
    Liao, Anyan
    Zhao, Jing
    Jiang, Leilei
    Dong, Xin
    Deng, Wei
    Yu, Huiming
    Yu, Rong
    Zhao, Jun
    Shi, Anhui
    BMC CANCER, 2023, 23 (01)
12345